Regentis Biomaterials Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Public

  • Employees
  • 7

Employees

  • Stock Symbol
  • RGNT

Stock Symbol

  • Share Price
  • $1.22
  • (As of Tuesday Closing)

Regentis Biomaterials General Information

Description

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 60, Medinat Hyahudim
  • Entrance C
  • Herzlia Pituach 4676652
  • Israel
+972
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Stock Exchange
ASE
Vertical(s)
Corporate Office
  • 60, Medinat Hyahudim
  • Entrance C
  • Herzlia Pituach 4676652
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Regentis Biomaterials Stock Performance

As of 17-Nov-2026, Regentis Biomaterials’s stock price is $1.22. Its current market cap is $8.57M with 7.02M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.22 $1.19 $1.14 - $15.50 $8.57M 7.02M 49.4K -$2.46

Regentis Biomaterials Financials Summary

As of 30-Jun-2026, Regentis Biomaterials has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 18,613 77,982
Revenue 0 0 0 0
EBITDA (12,704) (13,324) 4,972 (3,959)
Net Income (13,020) (13,648) 4,801 (4,132)
Total Assets 9,350 7,618 482 360
Total Debt 29 1,197 4,945 7,615
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Regentis Biomaterials Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Regentis Biomaterials‘s full profile, request access.

Request a free trial

Regentis Biomaterials Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Regentis Biomaterials‘s full profile, request access.

Request a free trial

Regentis Biomaterials Patents

Regentis Biomaterials Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3018305-A1 Treatments utilizing a polymer-protein conjugate Inactive 30-Mar-2016
EP-3436076-A1 Treatments utilizing a polymer-protein conjugate Inactive 30-Mar-2016
US-20190083642-A1 Treatments utilizing a polymer-protein conjugate Inactive 30-Mar-2016
WO-2017168428-A1 Treatments utilizing a polymer-protein conjugate Inactive 30-Mar-2016
WO-2017168428-A9 Treatments utilizing a polymer-protein conjugate Inactive 30-Mar-2016 A61K47/6435
To view Regentis Biomaterials’s complete patent history, request access »

Regentis Biomaterials Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Regentis Biomaterials ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Regentis Biomaterials’s complete esg history, request access »

Regentis Biomaterials FAQs

  • When was Regentis Biomaterials founded?

    Regentis Biomaterials was founded in 2004.

  • Where is Regentis Biomaterials headquartered?

    Regentis Biomaterials is headquartered in Herzlia Pituach, Israel.

  • What is the size of Regentis Biomaterials?

    Regentis Biomaterials has 7 total employees.

  • What industry is Regentis Biomaterials in?

    Regentis Biomaterials’s primary industry is Therapeutic Devices.

  • Is Regentis Biomaterials a private or public company?

    Regentis Biomaterials is a Public company.

  • What is Regentis Biomaterials’s stock symbol?

    The ticker symbol for Regentis Biomaterials is RGNT.

  • What is the current stock price of Regentis Biomaterials?

    As of 17-Nov-2026 the stock price of Regentis Biomaterials is $1.22.

  • What is the current market cap of Regentis Biomaterials?

    The current market capitalization of Regentis Biomaterials is $8.57M.

  • What is Regentis Biomaterials’s annual earnings per share (EPS)?

    Regentis Biomaterials’s EPS for 12 months was -$2.46.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process